Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Registration-Directed Study to Investigate Leronlimab Single-Agent Maintenance Therapy for HIV-Infected Patients

Trial Profile

A Registration-Directed Study to Investigate Leronlimab Single-Agent Maintenance Therapy for HIV-Infected Patients

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leronlimab (Primary)
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 20 Nov 2018 According to a CytoDyn media release, the company is hopeful to have final approval for treating with leronlimab monotherapy in 2020.
    • 13 Nov 2018 According to a CytoDyn media release, based on the promising results of the investigative monotherapy trial (investigative monotherapy trial), the company plans to submit a pivotal monotherapy trial protocol for PRO 140 as a single-agent maintenance therapy before the end of 2018 with the intention of filing for a label expansion subject to combination therapys first approval.
    • 16 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top